Overview

A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment

Status:
Terminated

Trial end date:
2017-03-15

Target enrollment:

Participant gender:

Summary

The purpose of the study was to understand if there is benefit in treatment with a medicine called enzalutamide in the re-treatment setting. Patients must have been previously treated with enzalutamide in the pre-chemotherapy setting for a minimum of 8 months and have disease progressed, followed by docetaxel and/or cabazitaxel for at least 4 cycles.

Phase:

Phase 4

Details

Lead Sponsor:

Astellas Pharma Global Development, Inc.

Collaborator:

Medivation, Inc.